Wuxi Biologics Sustainability Profile
Wuxi Biologics, officially known as WuXi AppTec Co., Ltd., is a leading global contract research, development, and manufacturing organisation (CDMO) headquartered in Wuxi, China. Founded in 2010, the company has rapidly expanded its operations across major regions, including the United States and Europe, establishing itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Their unique integrated platform streamlines the drug development process, enabling clients to bring innovative therapies to market more efficiently. With a strong commitment to quality and innovation, Wuxi Biologics has achieved significant milestones, including numerous partnerships with leading pharmaceutical companies, solidifying its position as a trusted partner in the global biopharmaceutical landscape.
DitchCarbon Score
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wuxi Biologics's score of 54 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wuxi Biologics's reported carbon emissions
In 2024, Wuxi Biologics reported total greenhouse gas emissions of approximately 198,654,000 kg CO2e, comprising 38,346,000 kg CO2e from Scope 1 and 160,308,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions included 24,700,000 kg CO2e from business travel, 19,176,000 kg CO2e from employee commuting, and 58,680,000 kg CO2e from fuel and energy-related activities, among other categories. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 GHG emission intensity by 50% by 2030 from a 2020 baseline. Furthermore, Wuxi Biologics has committed to achieving net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a 58.8% reduction in absolute Scope 1 and 2 emissions by 2034 from a 2024 base year, and a 63.8% reduction in Scope 3 emissions related to purchased goods and services per kg of product produced within the same timeframe. Wuxi Biologics' targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, demonstrating the company's commitment to significant climate action in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Wuxi Biologics's Industry?
How Carbon Intensive is Wuxi Biologics's Location?
Wuxi Biologics's Scope 3 Categories Breakdown
Wuxi Biologics's Scope 3 emissions, which increased by 9% last year and increased by approximately 164% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Fuel and Energy Related Activities" being the largest emissions source at 55% of Scope 3 emissions.
Top Scope 3 Categories
Wuxi Biologics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Wuxi Biologics has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Frequently Asked Questions
Common questions about Wuxi Biologics's sustainability data and climate commitments